Últimas noticias sobre CA Immobilien Anlagen (OTC:CAIAF) Bolsa

CA Immobilien Anlagen AG is a real estate company involved in owning, developing and managing, especially office properties in Austria and Germany as well as in Eastern Europe. The company generates revenues and other income from rental activities, the sale of properties held for trading, the sale of properties, as well as from development services. The company has two segments: the Eastern Europe core region segment, that consists of Poland and Czechia ; and the Eastern Europe other region segment, that consists of Hungary and Serbia.

CA IMMOBILIEN ANLAGEN AG by CA Immobilien Anlagen AG

CA Immobilien Anlagen AG

BMO Capital analyst Devin Dodge maintains Waste Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) with a Market Perform and raises the price target from $241 to $245.

News

Price Target

Analyst Ratings

BMO Capital Maintains Market Perform on Waste Management, Raises Price Target to $245

WIIM

SITM

SiTime shares are trading lower after the company announced the launch of a follow-on public offering.

BMO Capital analyst Ameet Thakkar maintains Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) with a Market Perform and raises the price target from $4 to $5.

FLNC

BMO Capital Maintains Market Perform on Fluence Energy, Raises Price Target to $5

Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) <a href="https://www.benzinga.com/quote/AMZN/news">stock may be dragging</a> in 2025, but JPMorgan is doubling down on what it calls the company's "best idea": Prime.
Despite being down 3% year-to-date, analyst Doug Anmuth sees upside to $240 — a roughly 13% climb from current levels. The core driver is, surprisingly, the same $139 subscription many Americans barely think about after checkout.
<h2 class="wp-block-heading">$139 In, $1,430 Out — The Prime Value Bomb</h2>
JPMorgan's deep dive estimates the true annual value of a U.S. Prime subscription is now $1,430 — more than 10x the cost. "That's a 6% jump from 2024 and more than double the value in 2016," says Anmuth. The report suggests Amazon is delivering the fastest fulfillment speeds in company history, with over 9 billion same-day/one-day deliveries in 2024 alone.
And it's not just about shipping anymore. Prime now comes bundled with Grubhub+, grocery delivery, Prime Video (NFL, NBA, NASCAR), music, photo storage, and more. If Apple One is bundling basics, Amazon's bundling the entire mall.
Read Also: <a href="https://www.benzinga.com/etfs/sector-etfs/25/06/46098656/nvidia-amazon-tesla-among-tech-stocks-hedge-funds-are-piling-into-heres-how-etfs-like-ivv-spy-voo-are-riding-the-wave">Nvidia, Amazon, Tesla Among Tech Stocks Hedge Funds Are Piling Into — Here&#8217;s How ETFs Like IVV, SPY, VOO Are Riding The Wave</a>
<h2 class="wp-block-heading">A Price Hike Is Coming — And That's Bullish</h2>
JPMorgan expects a Prime price increase in 2026, consistent with Amazon's every-four-years cadence. But here's the kicker: no major churn expected. Anmuth estimates that even a modest $20 hike could generate $3 billion in incremental annual sales.
Despite competition from Walmart Inc&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) Walmart+, Costco Wholesale Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) and Apple Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) Apple One, Anmuth believes Prime still leads the value race. With Prime members nearing 350 million globally by 2025, and international penetration still low, there's plenty of room for subscriber growth too.
So while Amazon's stock may be taking a breather, its subscription flywheel is spinning harder than ever. As JPMorgan puts it, "Prime remains the best deal in shopping"—and maybe in investing too.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/06/46093421/ai-will-disrupt-25-of-us-jobs-by-2030-and-the-fed-cant-save-them-economist-warns">AI Will Disrupt 25% Of US Jobs By 2030—And The Fed Can&#8217;t Save Them, Economist Warns</a></li>
</ul>
Image: Shutterstock

Analyst Color

Long Ideas

Tech

Trading Ideas

AAPL

AMZN

COST

Prime Time For Amazon? JPMorgan Says Your $139 Could Be Worth $1,430

BMO Capital analyst Andrew Strelzik maintains Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Market Perform and raises the price target from $190 to $215.

BMO Capital Maintains Market Perform on Darden Restaurants, Raises Price Target to $215

<h3>Gainers</h3>
<ul>
<li>Bumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) shares increased by 21.6% to $6.34 during Wednesday's regular session. The company's market cap stands at $538.1 million. </li>
<li>So-Young Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SY#NASDAQ">SY</a>) stock increased by 13.11% to $1.94. The market value of their outstanding shares is at $175.4 million. </li>
<li>Lee Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEE#NASDAQ">LEE</a>) stock increased by 10.87% to $6.73. The market value of their outstanding shares is at $37.7 million. </li>
<li>EPWK Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPWK#NASDAQ">EPWK</a>) shares rose 10.38% to $0.55. The market value of their outstanding shares is at $11.0 million. </li>
<li>Harte-Hanks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HHS#NASDAQ">HHS</a>) stock rose 9.11% to $3.95. The company's market cap stands at $26.6 million. </li>
<li>Intelligent Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTJ#NASDAQ">INTJ</a>) shares rose 8.71% to $1.0. The company's market cap stands at $12.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Fast Track (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRK#NASDAQ">FTRK</a>) stock declined by 36.0% to $1.6 during Wednesday's regular session. The company's market cap stands at $53.1 million. </li>
<li>Oriental Culture Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCG#NASDAQ">OCG</a>) shares fell 12.94% to $5.52. The market value of their outstanding shares is at $131.4 million. </li>
<li>System1 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SST#NYSE">SST</a>) shares fell 12.87% to $8.16. The market value of their outstanding shares is at $74.6 million. </li>
<li>VS Media Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSME#NASDAQ">VSME</a>) stock decreased by 11.69% to $0.94. The company's market cap stands at $47.9 million. </li>
<li>Intelligent Protection (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPM#NASDAQ">IPM</a>) stock fell 10.82% to $1.98. The company's market cap stands at $29.3 million. </li>
<li>LZ Technology Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZMH#NASDAQ">LZMH</a>) shares decreased by 10.35% to $12.53. The company's market cap stands at $2.1 billion. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BMBL

EPWK

FTRK

INTJ

LZMH

VSME

12 Communication Services Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock increased by 66.2% to $0.31 during Wednesday's regular session. The company's market cap stands at $1.1 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) shares moved upwards by 58.75% to $0.51. The company's market cap stands at $39.7 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares increased by 33.07% to $8.26. The company's market cap stands at $3.5 million. </li>
<li>VYNE Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) stock moved upwards by 33.01% to $1.41. The company's market cap stands at $17.6 million. </li>
<li>Anbio Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNNN#NASDAQ">NNNN</a>) shares moved upwards by 30.93% to $31.53. The company's market cap stands at $1.0 billion. </li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) stock increased by 26.86% to $31.02. The market value of their outstanding shares is at $303.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Annovis Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANVS#NYSE">ANVS</a>) stock declined by 26.1% to $2.26 during Wednesday's regular session. The market value of their outstanding shares is at $59.6 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) stock decreased by 25.69% to $10.53. The market value of their outstanding shares is at $93.2 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock fell 25.2% to $0.51. The market value of their outstanding shares is at $20.8 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) stock decreased by 21.14% to $4.38. The market value of their outstanding shares is at $3.0 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) stock declined by 17.65% to $2.1. The company's market cap stands at $18.9 million. </li>
<li>Concord Medical Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) shares declined by 15.93% to $4.91. The market value of their outstanding shares is at $253.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANVS

BBLG

FBRX

GCTK

NKTR

NNNN

ONMD

PSTV

VYNE

12 Health Care Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Falcons Beyond Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBYD#NASDAQ">FBYD</a>) stock moved upwards by 26.5% to $6.59 during Wednesday's regular session. The company's market cap stands at $193.9 million. </li>
<li>AeroVironment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) shares increased by 24.56% to $240.76. The company's market cap stands at $8.8 billion. The company's, Q4 earnings came out yesterday. </li>
<li>OFA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFAL#NASDAQ">OFAL</a>) stock increased by 15.69% to $1.82. The company's market cap stands at $21.8 million. </li>
<li>Arrive AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAI#NASDAQ">ARAI</a>) shares rose 15.49% to $9.38. The company's market cap stands at $267.8 million. </li>
<li>Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) stock rose 13.19% to $4.08. The company's market cap stands at $69.4 million. </li>
<li>Fuel Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEK#NASDAQ">FTEK</a>) shares moved upwards by 12.76% to $2.65. The market value of their outstanding shares is at $72.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Globavend Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVH#NASDAQ">GVH</a>) stock declined by 36.0% to $0.8 during Wednesday's regular session. The company's market cap stands at $18.7 million. </li>
<li>Robin Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBNE#NASDAQ">RBNE</a>) stock fell 14.95% to $4.12. The market value of their outstanding shares is at $16.2 million. </li>
<li>Air T (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRT#NASDAQ">AIRT</a>) stock decreased by 13.1% to $19.31. </li>
<li>Nuvve Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) stock declined by 9.71% to $0.93. The market value of their outstanding shares is at $9.7 million. </li>
<li>JVSPAC Acquisition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JVSA#NASDAQ">JVSA</a>) stock fell 9.39% to $11.3. The company's market cap stands at $95.8 million. </li>
<li>Galaxy Payroll Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLXG#NASDAQ">GLXG</a>) shares decreased by 8.95% to $0.51. The market value of their outstanding shares is at $10.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRT

ARAI

AVAV

FBYD

FTEK

GLXG

JVSA

NVVE

OFAL

RBNE

SRFM

12 Industrials Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>X3 Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTKG#NASDAQ">XTKG</a>) shares increased by 22.6% to $1.57 during Wednesday's regular session. The company's market cap stands at $46.1 million. </li>
<li>Inuvo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INUV#AMEX">INUV</a>) stock moved upwards by 20.85% to $4.52. The company's market cap stands at $53.9 million. </li>
<li>Sonim Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONM#NASDAQ">SONM</a>) shares rose 16.96% to $1.31. The company's market cap stands at $11.5 million. </li>
<li>Aeluma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMU#NASDAQ">ALMU</a>) stock moved upwards by 16.44% to $16.29. The company's market cap stands at $220.9 million. </li>
<li>Lianhe Sowell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LHSW#NASDAQ">LHSW</a>) shares rose 15.33% to $1.73. The market value of their outstanding shares is at $78.0 million. </li>
<li>T Stamp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDAI#NASDAQ">IDAI</a>) shares increased by 15.11% to $2.59. The company's market cap stands at $5.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>XTI Aerospace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) shares decreased by 35.7% to $1.8 during Wednesday's regular session. The company's market cap stands at $22.8 million. </li>
<li>Nano Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) shares decreased by 17.04% to $12.32. The company's market cap stands at $247.7 million. </li>
<li>SiTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SITM#NASDAQ">SITM</a>) shares declined by 14.22% to $207.25. The company's market cap stands at $5.7 billion. </li>
<li>Ascent Solar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTI#NASDAQ">ASTI</a>) shares decreased by 12.51% to $1.4. The market value of their outstanding shares is at $2.9 million. </li>
<li>Alpha Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATGL#NASDAQ">ATGL</a>) shares declined by 12.47% to $21.0. The company's market cap stands at $394.9 million. </li>
<li>Sequans Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQNS#NYSE">SQNS</a>) stock declined by 11.38% to $1.48. The company's market cap stands at $103.4 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALMU

ASTI

ATGL

IDAI

INUV

LHSW

SONM

SQNS

XTIA

XTKG

12 Information Technology Stocks Moving In Wednesday's Intraday Session

BMO Capital analyst Rene Cartier downgrades Triple Flag Precious (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TFPM#TSX">TFPM</a>) from Outperform to Market Perform and raises the price target from C$33 to C$35.

Downgrades

TSX:TFPM

BMO Capital Downgrades Triple Flag Precious to Market Perform, Raises Price Target to C$35

Stifel analyst Jonathan Siegmann reiterated the Buy rating on AeroVironment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) on Wednesday <a target="_blank" href="https://www.benzinga.com/quote/AVAV/analyst-ratings" rel="noreferrer noopener">with a price forecast of $240</a>.
The company released its fourth-quarter results after Tuesday&#8217;s closing bell. AeroVironment reported quarterly earnings of $1.61 per share, <a href="https://www.benzinga.com/markets/earnings/25/06/46083155/aerovironment-stock-sinks-despite-better-than-expected-q4-report-heres-why" target="_blank" rel="noreferrer noopener">which beat the $1.42 analyst consensus estimate</a>.
Quarterly revenue came in at &nbsp;$275.05 million, beating the Street estimate of&nbsp;$242.69 million.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/25/06/45896929/trump-launches-aviation-overhaul-archer-joby-new-horizon-aerovironment-rally-as-us-targets-drone-evtol-supersonic-comeback" rel="noreferrer noopener">Trump Launches Aviation Overhaul: Archer, Joby, New Horizon, AeroVironment Rally As US Targets Drone, eVTOL, Supersonic Comeback</a>
The analyst reiterated a Buy rating on AeroVironment, citing its strong positioning as a pure-play next-gen defense tech firm with accelerating sales and earnings, which he predicts to fuel investor interest and support multiple expansions.
In the recently reported quarter, Siegmann noted that the outperformance was entirely due to stronger-than-expected Loitering Munitions, or LMS, revenue of $138 million, well above their $95 million forecast.
Following the update, management issued the fiscal year 2026 guidance, which aligned with Siegmann&#8217;s earlier projections and the previously filed S-4.
The analyst also viewed the planned acceleration in capital expenditure spending positively, expecting investors to increasingly favor organic growth efforts in next-gen defense technology.
Adjusted EBITDA of $62 million (22.4% margin) surpassed Siegmann&#8217;s estimate of $53 million (22.5%) and the $55 million consensus (22.7%). The beat was mainly due to stronger revenue and lower SG&amp;A and R&amp;D costs as a percentage of sales, though partially offset by a lower gross margin of 39.5% versus the expected 42.0%.
Siegmann also noted that fourth quarter adjusted EBITDA was higher than all but four of the company&#8217;s annual EBITDA results since fiscal year 2025.
On the earnings call, analysts questioned the sharp 48% quarter-over-quarter drop in the company&#8217;s unfunded backlog.
Management explained this was tied to the expiration of an Army IDIQ contract under PEO Missiles &amp; Space for Switchblade drones.
The Army has since shifted procurement to a different IDIQ contract managed by PEO Soldier.
According to the analyst, all Switchblade-related obligations in the current U.S. government fiscal year have come through the PEO Soldier contract, highlighting continued demand under the new vehicle.
The recent merger with BlueHalo expands the company&#8217;s footprint into key defense areas like space, counter-drone systems, and missiles, core priorities for the Department of Defense.
Siegmann expects a sharp increase in organic EBITDA contributions from both the legacy AeroVironment business and the newly added BlueHalo operations.
Price Action: AVAV shares are trading higher by 21.6% to $234.97&nbsp;at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/46094069/iran-breaks-silence-says-nuclear-facilities-badly-damaged-by-us-strikes" target="_blank" rel="noreferrer noopener">Iran Breaks Silence, Says Nuclear Facilities &#8216;Badly Damaged&#8217; By US Strikes</a></li>
</ul>
Image via Shutterstock

Equities

Reiteration

Markets

General

This Defense Tech Innovator Just Crushed Earnings: What's Next?

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares are trading lower Wednesday after the electric vehicle maker reported its fifth consecutive month of declining <a href="https://www.benzinga.com/markets/tech/25/06/46087914/teslas-europe-sales-slide-for-5th-straight-month-elon-musk-led-ev-giants-market-share-shrinks-to-1-3">sales in the European market</a>.
What To Know: Tesla's new vehicle sales fell 27.9% year-over-year in Europe last month, despite the broader electric vehicle segment growing by 27.2% in the region, according to Reuters, citing data from the European Automobile Manufacturers Association (ACEA).
The company's latest Model Y update has yet to reverse the downward trend for Tesla that started when buyers began protesting CEO Elon Musk&#8217;s political involvement. 
The broader European market saw a modest 1.9% increase in overall new car sales last month, while Tesla's market share in Europe dropped to just 1.2%, compared to 1.8% in the same month last year.
Tesla's performance diverged sharply from that of its competitors. Reuters reported that legacy automakers and Chinese EV firms continued to gain ground, particularly in the lower-cost segment. 
The decline highlights ongoing challenges for Tesla in Europe, including rising competition from state-backed Chinese manufacturers like SAIC, pricing pressure across the EV market and shifting consumer sentiment. 
The decline in Tesla shares on Wednesday comes after shares <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46058796/tesla-stock-is-surging-today-whats-driving-the-momentum">moved higher</a> to start the week following the company&#8217;s &#8220;successful&#8221; robotaxi launch in Austin. 
Analysts had mixed reactions to the event with Wedbush's Dan Ives predicting that the rollout will accelerate as he suggested that Tesla&#8217;s autonomous arm is worth $1 trillion alone. Ives maintained an Outperform rating on Tesla with a price target of $500.
Meanwhile, UBS maintained a Sell rating following the robotaxi launch and lifted its price target to $215, while Guggenheim reiterated a Sell rating with a price target of $175.
TSLA Price Action: Tesla shares were down 4.14% at $326.40 at the time of publication Wednesday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/46099022/best-ai-stocks-nvidia-semiconductors-top-performers">The AI Rally Just Flipped—These Stocks Are Now Outgunning Nvidia</a></li>
</ul>
Image via Shutterstock.

TSLA

Tesla Stock Is Sliding Wednesday: What's Going On?

Oppenheimer analyst Noah Kaye maintains Waste Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) with a Outperform and raises the price target from $251 to $255.

Oppenheimer Maintains Outperform on Waste Management, Raises Price Target to $255

Carlyle Secured Lending's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CGBD#NYSE">CGBD</a>) short percent of float has fallen 3.92% since its last report. The company recently reported that it has 357 thousand shares sold short, which is 0.49% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.14 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Carlyle Secured Lending Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750870884_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Carlyle Secured Lending has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Carlyle Secured Lending's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Carlyle Secured Lending's peer group average for short interest as a percentage of float is 2.27%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

CGBD

What Does the Market Think About Carlyle Secured Lending?

Starbucks's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NYSE">SBUX</a>) short percent of float has fallen 12.44% since its last report. The company recently reported that it has 38.34 million shares sold short, which is 3.38% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.9 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Starbucks Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750870879_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Starbucks has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Starbucks's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Starbucks's peer group average for short interest as a percentage of float is 9.64%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

SBUX

Peering Into Starbucks's Recent Short Interest

In the current session, Watsco Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSO#NYSE">WSO</a>) is trading at $429.67, after a 0.36% drop. Over the past month, the stock decreased by 4.95%, and in the past year, by 8.87%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1750870878_0.png" alt="Past Year Chart" />

<h3>Comparing Watsco P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Watsco has a lower P/E than the aggregate P/E of 105.09 of the Trading Companies &amp; Distributors industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1750870879_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

P/E Ratio Insights for Watsco

Veeva Systems's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) short percent of float has risen 21.28% since its last report. The company recently reported that it has 5.33 million shares sold short, which is 3.59% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.5 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Veeva Systems Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750870874_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Veeva Systems has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Veeva Systems's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Veeva Systems's peer group average for short interest as a percentage of float is 7.12%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

VEEV

What's Driving the Market Sentiment Around Veeva Systems?

Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) on Wednesday initiated the VANQUISH Phase 3 clinical program for VK2735, the company&#8217;s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n46091315/viking-therapeutics-announces-initiation-of-phase-3-obesity-clinical-program-with-glp-1gip-agonist" rel="noreferrer noopener">polypeptide (GIP) receptors</a>.
VK2375 is being developed in oral and subcutaneous formulations for metabolic <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">disorders such as obesity</a>.
The VANQUISH Phase 3 program includes two studies evaluating VK2735: one in adults with obesity and one in obese or overweight adults with type 2 diabetes.&nbsp;
Each study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy and safety of VK2735 administered by subcutaneous injection once weekly for 78 weeks.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/01/42827918/viking-therapeutics-structure-therapeutics-positioned-as-key-pharma-partners-for-weight-loss-products-analyst" target="_blank" rel="noreferrer noopener">Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst</a>
VANQUISH-1 study: The study will target enrollment of approximately 4,500 obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) adults with at least one weight-related co-morbid condition.
VANQUISH-2 study: The study will target enrollment of approximately 1,100 adults with type 2 diabetes who are obese or overweight. 
Participants in both trials will be randomized to one of four weekly treatment arms: VK2735 7.5 mg, VK2735 12.5 mg, VK2735 17.5 mg, and placebo, slightly higher than the currently approved Eli Lilly And Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound doses of 5 mg, 10 mg and 15 mg.
The trials&#8217; primary endpoint is the percent change in body weight from baseline for participants receiving VK2735 compared to placebo after 78 weeks of treatment.
Secondary and exploratory endpoints will evaluate additional safety and efficacy measures, including the percentage of patients who achieve ≥5%, ≥10%, ≥15% and ≥20% body weight reduction.&nbsp;
Each study will include an open-label extension, allowing participants to continue receiving treatment after the primary dosing period is completed.
In 2024, Viking announced topline results from the Phase 2 VENTURE study of subcutaneous VK2735 in obesity.
The VENTURE trial successfully achieved its primary and all secondary endpoints, with patients receiving VK2735 demonstrating clinically meaningful reductions in body weight compared with placebo.
Patients receiving VK2735 demonstrated statistically significant reductions in mean body weight from baseline, ranging up to 14.7%, and statistically significant reductions in mean body weight relative to placebo, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41712739/viking-therapeutics-reveals-early-stage-from-experimental-oral-obesity-drug-showing-weight-loss-a" rel="noreferrer noopener">ranging up to 13.1%</a>.
Differences compared to placebo were statistically significant for all doses starting at week one and were maintained throughout the study.
In addition, results from follow-up visits four and seven weeks after the last dose of VK2735 was administered showed that cohorts receiving VK2735 maintained the majority of their weight loss through the seven-week follow-up visit after administering the final dose.
VK2735 also demonstrated encouraging safety and tolerability in the VENTURE study, with most observed adverse events (AEs) being reported as mild or moderate.
Treatment and study discontinuation rates among VK2735 cohorts were well-balanced compared with placebo. Of gastrointestinal (GI) related AEs, 95% were reported as mild or moderate.
Why it Matters: William Blair notes some obesity experts said that insurance companies often won't cover certain &#8220;non-standard&#8221; Zepbound doses like 2.5 mg, 7.5 mg and 12.5 mg, even though these may be the best long-term doses for some patients.
While large academic hospitals with specialized reimbursement teams can usually work around this issue, smaller or community clinics may benefit from approving these in-between doses, as it could make treatment more accessible for more patients.
Analyst Andy Hsieh expects that 17.5 mg VK2735 could contribute to additional weight loss over 15 mg Zepbound and surmises there could be a potential ceiling effect when it comes to increasingly higher doses of Zepbound or VK2735.
&#8220;We continue to believe that Viking's obesity franchise offers a unique set of attractive qualities that will be viewed favorably in the lens of big pharma from an M&amp;A perspective&#8230;,&#8221; William Blair analyst wrote on Wednesday.
VKTX Price Action: VKTX stock is down 1% at $26.68 at publication on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/46097698/bumble-is-breaking-up-with-30-staff-investors-swipe-right" target="_blank" rel="noreferrer noopener">Bumble Is &#8216;Breaking Up&#8217; With 30% Staff, Investors Swipe Right</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

VKTX

What's Going On With Viking Therapeutics Stock On Wednesday?

CNBC Halftime Report Final Trades: Taiwan Semiconductor Manufacturing, Advanced Micro Devices, American Express

Raymond James analyst Patrick Tyler Brown maintains FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) with a Outperform and lowers the price target from $275 to $260.

Raymond James Maintains Outperform on FedEx, Lowers Price Target to $260

CA Immobilien Anlagen

Comments

CA Immobilien Anlagen

Noticias

Últimas noticias sobre CA Immobilien Anlagen (OTC:CAIAF) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL